Amryt Earns Wings For Butterfly Skin Drug In Europe

CHMP Recommends Approval Of Filsuvez

CEO Joe Wiley has said the backing of the EMA's advisory committee for its epidermolysis bullosa gel represents "the most significant milestone in Amryt’s history" and is a massive boost for the Dublin-headquartered group after getting a complete response letter in the US a couple of months ago.

butterfly
• Source: Shutterstock

Rejected by US regulators in February, Amryt Pharma's butterfly skin therapy Filsuvez has been recommended in Europe to the delight of the Irish firm and patients with the rare and devastating hereditary disorder.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip